Bill Text: NY S04096 | 2019-2020 | General Assembly | Amended

New York Senate Bill 4096 (Prior Session Legislation)

Bill Title: Requires that for the first opioid analgesic prescription of a calendar year, the prescribing physician shall counsel the patient on the risks of overdose, and inform the patient of the availability of an opioid antagonist, including, but not limited to, naloxone.

Spectrum: Partisan Bill (Republican 1-0)

Status: (Introduced - Dead) 2020-02-12 - PRINT NUMBER 4096A [S04096 Detail]

Download: New_York-2019-S04096-Amended.html




                STATE OF NEW YORK
        ________________________________________________________________________

                                         4096--A

                               2019-2020 Regular Sessions

                    IN SENATE

                                    February 28, 2019
                                       ___________

        Introduced  by  Sen.  RANZENHOFER -- read twice and ordered printed, and
          when printed to be  committed  to  the  Committee  on  Alcoholism  and
          Substance  Abuse  --  recommitted  to  the Committee on Alcoholism and
          Substance Abuse in accordance with Senate Rule 6, sec. 8 --  committee
          discharged, bill amended, ordered reprinted as amended and recommitted
          to said committee

        AN  ACT  to amend the public health law, in relation to opioid analgesic
          prescriptions

          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:

     1    Section  1.  The  public health law is amended by adding a new section
     2  3309-b to read as follows:
     3    § 3309-b. Opioid analgesic prescription. 1. For the first opioid anal-
     4  gesic prescription of a calendar year that is greater than a one  week's
     5  supply, the prescribing physician shall counsel the patient on the risks
     6  of  overdose,  and  inform  the patient of the availability of an opioid
     7  antagonist, including, but not limited to, naloxone.
     8    2. For the purposes of this section, the following  terms  shall  have
     9  the following meanings:
    10    (a)  "Opioid  analgesics" means the medicines buprenorphine, butorpha-
    11  nol,  codeine,  hydrocodone,  hydromorphone,  levorphanol,   meperidine,
    12  methadone,  morphine,  nalbuphine,  oxycodone, oxymorphone, pentazocine,
    13  propoxyphene as well as their brand names, isomers and combinations.
    14    (b) "Opioid antagonist" means an FDA-approved drug that, when adminis-
    15  tered, negates or neutralizes in whole or in  part  the  pharmacological
    16  effects  of  an  opioid in the body. The opioid antagonist is limited to
    17  naloxone or other  medications  approved  by  the  department  for  this
    18  purpose.
    19    § 2. This act shall take effect on the one hundred twentieth day after
    20  it  shall have become a law. Effective immediately, the addition, amend-
    21  ment and/or repeal of any rule or regulation necessary for the implemen-
    22  tation of this act on its effective date are authorized to be  made  and
    23  completed on or before such effective date.

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD01776-04-0